Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 5/20 | 0.63 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.63 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6322852 | 1.00 | ADRB2 (0.63) | ADRB2ADRB1ADRB3CYP2D6KMT2A | |
| SCHEMBL6323866 | 0.93 | ADRB2 (0.58) | ADRB2ADRB1ADRB3CYP2D6KMT2A | |
| SCHEMBL6323862 | 0.93 | ADRB2 (0.58) | ADRB2ADRB1ADRB3CYP2D6KMT2A | |
| SCHEMBL6319499 | 0.92 | KMT2A (0.63) | ADRB2ADRB1ADRB3CYP2D6KMT2A | |
| SCHEMBL6319503 | 0.92 | KMT2A (0.63) | ADRB2ADRB1ADRB3CYP2D6KMT2A | |
| SCHEMBL7077354 | 0.90 | KMT2A (0.55) | ADRB2ADRB1ADRB3CYP2D6KMT2A | |
| SCHEMBL7077357 | 0.90 | KMT2A (0.55) | ADRB2ADRB1ADRB3CYP2D6KMT2A | |
| SCHEMBL6322829 | 0.90 | ADRB2 (0.54) | ADRB2ADRB1ADRB3CYP2D6KMT2A | |
| SCHEMBL6322832 | 0.90 | ADRB2 (0.54) | ADRB2ADRB1ADRB3CYP2D6KMT2A | |
| SCHEMBL6320439 | 0.88 | ADRB1 (0.52) | ADRB2ADRB1ADRB3CYP2D6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043371-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-02-24 | — | — | US | disclosed |
| US-20030181726-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-1107944-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000012462-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043371-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB1, ADRB3, ADRB2 | ADRB2 3/4885ADRB1 1/4885ADRB3 2/4885 |
| US-20030181726-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB1, ADRB3, ADRB2 | ADRB2 3/4885ADRB1 1/4885ADRB3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.